Myrexis Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2009
2010
2011
2012
2013
Sales/Revenue
5,456.00
90.00
185.00
-
-
Cost of Goods Sold (COGS) incl. D&A
-
-
22,296.00
1,282.00
387.00
Gross Income
-
-
22,111.00
1,282.00
387.00
SG&A Expense
60,738.00
46,859.00
17,239.00
25,119.00
10,805.00
EBIT
58,136.00
48,116.00
39,350.00
26,401.00
11,192.00
Unusual Expense
-
-
100.00
5,400.00
799.00
Non Operating Income/Expense
-
1,165.00
542.00
592.00
292.00
Pretax Income
58,136.00
46,951.00
38,708.00
31,209.00
11,621.00
Consolidated Net Income
58,136.00
46,951.00
38,708.00
31,209.00
11,621.00
Net Income
58,136.00
46,951.00
38,708.00
31,209.00
11,621.00
Net Income After Extraordinaries
58,136.00
46,951.00
38,708.00
31,209.00
11,621.00
Net Income Available to Common
58,136.00
46,951.00
38,708.00
31,209.00
11,621.00
EPS (Basic)
2.43
1.91
1.52
1.18
0.39
Basic Shares Outstanding
23,974.20
24,545.00
25,513.00
26,387.00
29,508.00
EPS (Diluted)
2.42
1.91
1.52
1.18
0.39
Diluted Shares Outstanding
23,974.20
24,545.00
25,513.00
26,387.00
29,508.00
EBITDA
55,282.00
46,769.00
37,689.00
25,119.00
10,805.00
Non-Operating Interest Income
-
-
-
-
78.00

About Myrexis

View Profile
Address
630 Fifth Avenue
New York New York 10020
United States
Employees -
Website http://www.myrexis.com
Updated 07/08/2019
Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. The company was founded in January 2009 and is headquartered in New York, NY. .